Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Show

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Fiji , Ohio , United States , Viti , Kori Wallace , Program To Assess Adverse Events , Twitter , Instagram , Facebook , Exchange Commission , Abbvie Inc , Linkedin , Arthritis Foundation , Youtube , Giant Cell Arteritis , Important Safety , Medication Guide , Consumer Brief Summary , Mississippi River , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Giant Cell , Accessed April , Takaysu Arteritis , Assess Adverse Events , Disease Activity , Adult Participants With Moderate , Severe Systemic Lupus Erythematosus , Assess Change , Adverse Events , Oral Upadacitinib , Adolescent Participants With Moderate , Severe Hidradenitis Suppurativa Who Have Failed , Study To Assess Adverse Events , Upadacitinib Oral Tablets , Adolescent Participants With Vitiligo , Upadacitinib Tablets ,